摘要
近些年免疫检查点抑制剂在肿瘤治疗领域取得了重大突破,包括恶性黑色素瘤、非小细胞肺癌等,近期并获得微卫星不稳定肿瘤的适应证。但与此同时也伴随一系列毒性的产生,主要为免疫相关不良反应,几乎累及各个系统,与传统化疗药物、靶向药物相关不良事件存在很大区别;同时尽管严重不良事件的发生率不高,但部分为致死性,且治疗干预缺乏足够的证据支持,临床认识不足。本文结合最新文献报道,从免疫检查点抑制剂的毒性风险特征、风险预测标志物、监测管理等方面进行综述。
Immune checkpoint inhibitors （CPIs） have obtained approval for the treatment of many kinds of malignant tumors, including melanoma, non-small cell lung cancer, et al. Recently, Keytruda（pembrolizumab） is indicated for the treatment of solid tumors that have been identified as microsatellite instability-high（MSI-H） tumors. Besides, these immune targeted agents also generate immune-related adverse events （ irAEs）, involving almost all organs, and differs much from side effects of conventional chemotherapy and targeted therapy. Although severe irAEs are rare, they can become life-threatening if not anticipated and managed appropriately, and management of irAEs are lack of sufficient evidence. We will review features, biomarkers and management of irAEs to provide referrence for clinical care of patients under CPIs.
出处
《临床肿瘤学杂志》
CAS
2017年第8期735-741,共7页
Chinese Clinical Oncology
